[1] P. v. Arriagada, K. Marzloff, and B. T. Hyman, “Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals match the pattern in Alzheimer’s disease,” Neurology, vol. 42, no. 9, pp. 1681–1681, Sep. 1992, doi: 10.1212/WNL.42.9.1681.
[2] E. Perry, “Acetylcholine and Alzheimer’s Disease,” The British Journal of Psychiatry, vol. 152, no. 6, pp. 737–740, 1988, doi: 10.1192/BJP.152.6.737.
[3] Z. Ismael, T. J. Millar, D. H. Small, and I. W. Chubb, “Acetylcholinesterase generates enkephalin-like immunoreactivity when it degrades soluble proteins (Chromogranins) from adrenal chromaffin granules,” Brain Res, vol. 376, no. 2, pp. 230–238, Jun. 1986, doi: 10.1016/0006-8993(86)90184-8.
[4] E. K. Perry et al., “Cholinergic receptors in cognitive disorders,” Canadian Journal of Neurological Sciences, vol. 13, no. S4, pp. 521–527, 1986, doi: 10.1017/s0317167100037240.
[5] F. Worek, U. Mast, D. Kiderlen, C. Diepold, and P. Eyer, “Improved determination of acetylcholinesterase activity in human whole blood,” Clinica Chimica Acta, vol. 288, no. 1–2, pp. 73–90, Oct. 1999, doi: 10.1016/S0009-8981(99)00144-8.
[6] B. Seltzer, “Donepezil: a review,” http://dx.doi.org/10.1517/17425255.1.3.527, vol. 1, no. 3, pp. 527–536, Oct. 2005, doi: 10.1517/17425255.1.3.527.
[7] A. Burns et al., “The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1,” Dement Geriatr Cogn Disord, vol. 10, no. 3, pp. 237–244, 1999, doi: 10.1159/000017126.
[8] J. Rodríguez-Pardo, I. Puertas-Muñoz, P. Martínez-Sánchez, J. D. de Terán, I. Pulido-Valdeolivas, and B. Fuentes, “Putamina involvement in Wernicke encephalopathy induced by Janus Kinase 2 inhibitor,” Clin Neuropharmacol, vol. 38, no. 3, pp. 117–118, May 2015, doi: 10.1097/WNF.0000000000000083.
[9] L. Sutthapitaksakul, C. R. Dass, and P. Sriamornsak, “Donepezil—an updated review of challenges in dosage form design,” J Drug Deliv Sci Technol, vol. 63, p. 102549, Jun. 2021, doi: 10.1016/J.JDDST.2021.102549.
[10] J. H. Lee, S. K. Jeong, B. C. Kim, K. W. Park, and A. Dash, “Donepezil across the spectrum of Alzheimer’s disease: dose optimization and clinical relevance,” Acta Neurol Scand, vol. 131, no. 5, pp. 259–267, May 2015, doi: 10.1111/ANE.12386.
[11] N. R. Dunn, G. L. Pearce, and S. A. W. Shakir, “Adverse effects associated with the use of donepezil in general practice in England,” http://dx.doi.org/10.1177/026988110001400410, vol. 14, no. 4, pp. 406–408, Jul. 2016, doi: 10.1177/026988110001400410.
[12] H. C. Li, K. X. Luo, J. S. Wang, and Q. X. Wang, “Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report,” Medicine, vol. 99, no. 11, p. e19443, Mar. 2020, doi: 10.1097/MD.0000000000019443.
[13] P. H. M. Torres, A. C. R. Sodero, P. Jofily, and F. P. Silva-Jr, “Key Topics in Molecular Docking for Drug Design,” International Journal of Molecular Sciences 2019, Vol. 20, Page 4574, vol. 20, no. 18, p. 4574, Sep. 2019, doi: 10.3390/IJMS20184574.
[14] L. G. Ferreira, R. N. dos Santos, G. Oliva, and A. D. Andricopulo, “Molecular Docking and Structure-Based Drug Design Strategies,” Molecules 2015, Vol. 20, Pages 13384-13421, vol. 20, no. 7, pp. 13384–13421, Jul. 2015, doi: 10.3390/MOLECULES200713384.
[15] T. Gaillard, “Evaluation of AutoDock and AutoDock Vina on the CASF-2013 Benchmark,” J Chem Inf Model, vol. 58, no. 8, pp. 1697–1706, Aug. 2018, doi: 10.1021/ACS.JCIM.8B00312/SUPPL_FILE/CI8B00312_SI_002.ZIP.
[16] R. Meyer and A. W. Hauser, “Geometry optimization using Gaussian process regression in internal coordinate systems,” J Chem Phys, vol. 152, no. 8, p. 084112, Feb. 2020, doi: 10.1063/1.5144603.
[17] S. Dallakyan and A. J. Olson, “Small-molecule library screening by docking with PyRx,” Methods in Molecular Biology, vol. 1263, pp. 243–250, 2015, doi: 10.1007/978-1-4939-2269-7_19/COVER.
[18] “EBSCOhost | 124927781 | Molecular docking analysis of Carica papaya Linn constituents as antiviral agent.” https://web.s.ebscohost.com/abstract?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=19854668&AN=124927781&h=s5U1gCbc6yeUEBu4h3IHdCYHB7tqmeYSXY%2b0PsOfyVz%2fJ%2b2gWkd%2bz70iUmhojHY0G%2f%2bCAkNXK3e5Do3EG1c5OA%3d%3d&crl=c&resultNs=AdminWebAuth&resultLocal=ErrCrlNotAuth&crlhashurl=login.aspx%3fdirect%3dtrue%26profile%3dehost%26scope%3dsite%26authtype%3dcrawler%26jrnl%3d19854668%26AN%3d124927781 (accessed Oct. 18, 2022).
[19] G. M. Morris, R. Huey, and A. J. Olson, “Using AutoDock for Ligand-Receptor Docking,” Curr Protoc Bioinformatics, vol. 24, no. 1, pp. 8.14.1-8.14.40, Dec. 2008, doi: 10.1002/0471250953.BI0814S24.